Evidence map›Paper›PMID 26631035›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Cooperative effect of BI-69A11 and celecoxib enhances radiosensitization by modulating DNA damage repair in colon carcinoma.

Ipsita Pal, Kaushik Kumar Dey, Madhuri Chaurasia, Sheetal Parida, Subhayan Das, Y Rajesh, Kulbhushan Sharma, Tamohan Chowdhury, Mahitosh Mandal

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ipsita PalSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India.
Kaushik Kumar DeySchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India.
Madhuri ChaurasiaDivision of Metabolic Cell Signaling Research, Institute of Nuclear Medicine and Allied Sciences, Delhi, 110054, India.
Sheetal ParidaSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India.
Subhayan DasSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India.
Y RajeshSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India.
Kulbhushan SharmaDivision of Metabolic Cell Signaling Research, Institute of Nuclear Medicine and Allied Sciences, Delhi, 110054, India.
Tamohan ChowdhurySaroj Gupta Cancer Center and Research Institute, Thakurpukur, Kolkata, West Bengal, India.
Mahitosh MandalSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, West Bengal, India. mahitosh@smst.iikgp.ernet.in.
Indian Institute of Technology Kharagpur · INInstitute of Nuclear Medicine & Allied Sciences · INSaroj Gupta Cancer Centre & Research Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amplification of PI3K-Akt pathway promotes radioresistance in various cancers including colorectal carcinoma. Local recurrence in colon cancer causes poor prognosis affecting overall survival of cancer-affected patient population. To avoid local recurrence, pre-operative or post-operative additional radiotherapy is given. However, main concern regarding radiotherapy is to increase the radiosensitivity of malignant cell without hampering the activities of normal cells. In this context, addition of two or more than two chemotherapeutic drugs as a radiosensitizer is a common practice in radiation biology. BI-69A11 earlier showed potential apoptosis-inducing effect in melanoma and colon carcinoma. Celecoxib showed anti-cancer effects in both COX-2 dependent and independent pathways and used to act as a radiosensitizing enhancer. Here, we suggest that the combination of BI-69A11 and celecoxib inhibits the phosphorylation of ataxia telangiectasia mutated (ATM) kinase and DNA-PK responsible for ionizing radiation (IR)-induced double-strand break (DSB) repair. Moreover, the combinatorial effect of BI-69A11 and celecoxib attenuates the IR-induced G2/M cell cycle arrest. Furthermore, this combination also impairs IR-induced activation of Akt and downstream targets of ATM. This might lead to induced activation of apoptotic pathway after triple therapy treatment modulating pro-apoptotic and anti-apoptotic proteins. This activation of apoptotic pathway also showed the interdependence of PUMA and BAD in triple combination-treated colon cancer cells in a p53 independent manner. This study reveals the therapeutic potential of the triple combination therapy in prevention of radioresistance. Besides, it also demonstrates the cytotoxic effects of triple combination therapy in colon cancer. This study shows utility and potential implication on safety of the patients undergoing radiation therapy.

Indexed as

ApoptosisBenzimidazolesCarcinomaCelecoxibColonic NeoplasmsCombined Modality TherapyDNA Breaks, Double-StrandedDNA DamageDNA RepairHCT116 CellsHumansQuinolonesRadiation, IonizingRadiation-Sensitizing AgentsRadiation ToleranceSignal Transduction3-(3-(1H-benzo(d)imidazol-2-yl)acryloyl)-6-chloro-4-phenylquinolin-2(1H)-oneBenzimidazolesCelecoxibQuinolonesRadiation-Sensitizing AgentsBI-69A11CelecoxibColon carcinomaDNA damage repairRadiosensitization

Identifiers

PMID26631035
OpenAlexW2185599350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.